CN115869398B - 抗garp抗体 - Google Patents

抗garp抗体 Download PDF

Info

Publication number
CN115869398B
CN115869398B CN202211442176.3A CN202211442176A CN115869398B CN 115869398 B CN115869398 B CN 115869398B CN 202211442176 A CN202211442176 A CN 202211442176A CN 115869398 B CN115869398 B CN 115869398B
Authority
CN
China
Prior art keywords
amino acid
seq
antibody
sequence
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211442176.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN115869398A (zh
Inventor
佐藤一纪
平原一树
渡边一郎
天野正人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CN115869398A publication Critical patent/CN115869398A/zh
Application granted granted Critical
Publication of CN115869398B publication Critical patent/CN115869398B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202211442176.3A 2015-09-24 2016-09-23 抗garp抗体 Active CN115869398B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2015187488 2015-09-24
JP2015-187488 2015-09-24
CN201680056149.9A CN108026521B (zh) 2015-09-24 2016-09-23 抗garp抗体
PCT/JP2016/078067 WO2017051888A1 (ja) 2015-09-24 2016-09-23 抗ｇａｒｐ抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680056149.9A Division CN108026521B (zh) 2015-09-24 2016-09-23 抗garp抗体

Publications (2)

Publication Number Publication Date
CN115869398A CN115869398A (zh) 2023-03-31
CN115869398B true CN115869398B (zh) 2025-04-22

Family

ID=58386752

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202211442176.3A Active CN115869398B (zh) 2015-09-24 2016-09-23 抗garp抗体
CN201911407390.3A Pending CN110922481A (zh) 2015-09-24 2016-09-23 抗garp抗体
CN201680056149.9A Active CN108026521B (zh) 2015-09-24 2016-09-23 抗garp抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201911407390.3A Pending CN110922481A (zh) 2015-09-24 2016-09-23 抗garp抗体
CN201680056149.9A Active CN108026521B (zh) 2015-09-24 2016-09-23 抗garp抗体

Country Status (28)

Country Link
US (4) US11046780B2 (https=)
EP (3) EP3354729B1 (https=)
JP (5) JP6878283B2 (https=)
KR (2) KR20250037587A (https=)
CN (3) CN115869398B (https=)
AU (3) AU2016325858B2 (https=)
BR (1) BR112018005777A2 (https=)
CA (1) CA2999819A1 (https=)
CO (1) CO2018003542A2 (https=)
DK (1) DK3354729T5 (https=)
ES (1) ES2978126T3 (https=)
FI (1) FI3354729T3 (https=)
HR (1) HRP20240495T1 (https=)
HU (1) HUE066594T2 (https=)
IL (3) IL288784B2 (https=)
LT (1) LT3354729T (https=)
MX (2) MX2018003594A (https=)
MY (1) MY194586A (https=)
PH (1) PH12018500642A1 (https=)
PL (1) PL3354729T3 (https=)
PT (1) PT3354729T (https=)
RS (1) RS65415B1 (https=)
RU (2) RU2022108079A (https=)
SG (2) SG11201802352VA (https=)
SI (1) SI3354729T1 (https=)
SM (1) SMT202400160T1 (https=)
TW (3) TWI751979B (https=)
WO (1) WO2017051888A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2860952T3 (es) 2013-08-01 2021-10-05 Univ Catholique Louvain Proteína anti-garp y usos de la misma
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
DK3354729T5 (da) * 2015-09-24 2024-09-30 Daiichi Sankyo Co Ltd Anti-garp-antistof
EP3436480A4 (en) * 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
GB201707561D0 (en) * 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
AU2018383709B2 (en) 2017-12-12 2025-09-11 Pionyr Immunotherapeutics, Inc. Anti-TREM2 antibodies and related methods
BR112020021266A2 (pt) * 2018-05-31 2021-01-26 Daiichi Sankyo Company, Limited anticorpo anti-tlr7 humano
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
US20240190961A1 (en) * 2019-10-25 2024-06-13 Daiichi Sankyo Company, Limited Combination of anti-garp antibody and immunomodulator
US20230192867A1 (en) * 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
KR20230035576A (ko) 2020-07-07 2023-03-14 비온테크 에스이 Hpv 양성 암 치료용 rna
WO2022116877A1 (en) 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
CA3204628A1 (en) 2021-01-13 2022-07-21 John T. POIRIER Antibody-pyrrolobenzodiazepine derivative conjugate
MX2023008285A (es) 2021-01-13 2023-09-12 Memorial Sloan Kettering Cancer Center Conjugado de anticuerpo anti-dll3-farmaco.
BR112023014319A2 (pt) * 2021-01-18 2023-09-26 Jiangxi Jemincare Group Co Ltd Anticorpo contra a proteína garp e aplicação do mesmo
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
JP2025526336A (ja) 2022-07-22 2025-08-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ
JP2026501506A (ja) 2022-12-14 2026-01-16 アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
US20250002588A1 (en) 2023-04-07 2025-01-02 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
TW202541837A (zh) 2023-12-08 2025-11-01 日商安斯泰來製藥公司 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1333274A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——人garp蛋白12.98和编码这种多肽的多核苷酸
CN104619722A (zh) * 2012-06-22 2015-05-13 达特茅斯大学理事会 新型vista-ig 构建体和vista-ig 用于治疗自身免疫性、过敏性和炎性疾病的用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2131151A1 (en) 1992-03-24 1994-09-30 Kevin S. Johnson Methods for producing members of specific binding pairs
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
SI1583830T1 (sl) 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
WO2006089678A2 (en) 2005-02-22 2006-08-31 Bioinvent International Ab Antibodies and peptides binding to hiv tat, and uses thereof
WO2006103639A2 (en) 2005-03-31 2006-10-05 Case Western Reserve University Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals
US20110086367A1 (en) 2006-04-03 2011-04-14 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
CN101679519A (zh) 2006-12-22 2010-03-24 先灵公司 Cd200r的抗体
WO2009087230A1 (en) 2008-01-11 2009-07-16 Morphosys Ag Display vectors and methods and uses thereof
WO2009111507A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
US20110287036A1 (en) 2008-11-17 2011-11-24 Riken Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
TWI480050B (zh) 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
CA2759836A1 (en) 2009-05-11 2010-11-18 U3 Pharma Gmbh Humanized axl antibodies
KR20130010121A (ko) 2010-03-23 2013-01-25 인트렉손 코포레이션 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
PH12013500845A1 (en) 2010-10-29 2013-06-24 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
US8440797B2 (en) 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
WO2012147713A1 (ja) 2011-04-25 2012-11-01 第一三共株式会社 抗ｂ７－ｈ３抗体
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
BR112014024267A8 (pt) 2012-03-30 2017-07-25 Daiichi Sankyo Co Ltd anticorpo ou um fragmento de ligação de antígeno do anticorpo, composição farmacêutica, usos de pelo menos um dos anticorpos ou fragmentos de ligação de antígeno e de uma composição, polinucleotídeo, vetor, e, célula hospedeira transformada
AU2013247645B2 (en) 2012-04-09 2019-02-14 Daiichi Sankyo Company, Limited Anti-FGFR2 antibody
WO2013160879A1 (en) 2012-04-27 2013-10-31 Daiichi Sankyo Company, Limited Anti-robo4-antibody
JP2014141434A (ja) * 2013-01-24 2014-08-07 Daiichi Sankyo Co Ltd 抗ｒｏｂｏ４抗体
WO2014061277A1 (ja) * 2012-10-19 2014-04-24 第一三共株式会社 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
JP2016500704A (ja) * 2012-11-06 2016-01-14 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 細胞シグナル伝達を変調するための組成物及び方法
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
ES2860952T3 (es) * 2013-08-01 2021-10-05 Univ Catholique Louvain Proteína anti-garp y usos de la misma
WO2016125017A1 (en) 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
DK3354729T5 (da) * 2015-09-24 2024-09-30 Daiichi Sankyo Co Ltd Anti-garp-antistof
EP3436480A4 (en) * 2016-03-30 2019-11-27 Musc Foundation for Research Development METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1333274A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——人garp蛋白12.98和编码这种多肽的多核苷酸
CN104619722A (zh) * 2012-06-22 2015-05-13 达特茅斯大学理事会 新型vista-ig 构建体和vista-ig 用于治疗自身免疫性、过敏性和炎性疾病的用途

Also Published As

Publication number Publication date
JP2025036561A (ja) 2025-03-14
WO2017051888A1 (ja) 2017-03-30
TWI836305B (zh) 2024-03-21
DK3354729T3 (da) 2024-04-22
JP7137657B2 (ja) 2022-09-14
JP2021106617A (ja) 2021-07-29
KR102776730B1 (ko) 2025-03-05
SG11201802352VA (en) 2018-04-27
AU2016325858B2 (en) 2022-05-26
TW202227501A (zh) 2022-07-16
EP4349997A3 (en) 2024-07-10
HRP20240495T1 (hr) 2024-07-05
IL258322A (en) 2018-05-31
JP6868739B2 (ja) 2021-05-12
JP6878283B2 (ja) 2021-05-26
RU2018114904A (ru) 2019-10-24
EP3660051A1 (en) 2020-06-03
MX2023003470A (es) 2023-04-19
PH12018500642A1 (en) 2018-09-24
TWI751979B (zh) 2022-01-11
CO2018003542A2 (es) 2018-07-10
RS65415B1 (sr) 2024-05-31
NZ741033A (en) 2025-05-30
JP2022169801A (ja) 2022-11-09
IL288784B1 (en) 2023-06-01
LT3354729T (lt) 2024-04-25
HK1254310A1 (en) 2019-07-19
ES2978126T3 (es) 2024-09-05
US20240360245A1 (en) 2024-10-31
US20180327511A1 (en) 2018-11-15
IL258322B2 (en) 2023-10-01
TW201718643A (zh) 2017-06-01
RU2022108079A (ru) 2022-04-08
SI3354729T1 (sl) 2024-05-31
KR20250037587A (ko) 2025-03-17
CN115869398A (zh) 2023-03-31
US12006372B2 (en) 2024-06-11
TW202438526A (zh) 2024-10-01
EP3354729A4 (en) 2019-06-12
TWI909341B (zh) 2025-12-21
AU2020200866A1 (en) 2020-02-27
BR112018005777A2 (pt) 2018-10-09
SG10201912570UA (en) 2020-02-27
US10550198B2 (en) 2020-02-04
RU2769379C2 (ru) 2022-03-30
NZ780546A (en) 2025-05-30
SMT202400160T1 (it) 2024-05-14
MX2018003594A (es) 2018-06-15
IL288784B2 (en) 2023-10-01
AU2022231706B2 (en) 2025-05-15
EP3354729B1 (en) 2024-02-14
EP4349997A2 (en) 2024-04-10
IL258322B1 (en) 2023-06-01
MY194586A (en) 2022-12-05
CN108026521B (zh) 2022-12-06
US20180258184A1 (en) 2018-09-13
PL3354729T3 (pl) 2024-05-20
AU2020200866B2 (en) 2022-06-16
HUE066594T2 (hu) 2024-08-28
CA2999819A1 (en) 2017-03-30
US20220010026A1 (en) 2022-01-13
AU2022231706A1 (en) 2022-10-06
US11046780B2 (en) 2021-06-29
JP2020202875A (ja) 2020-12-24
RU2018114904A3 (https=) 2020-03-03
JPWO2017051888A1 (ja) 2018-07-12
EP3354729A1 (en) 2018-08-01
KR20180053316A (ko) 2018-05-21
FI3354729T3 (fi) 2024-04-23
DK3354729T5 (da) 2024-09-30
PT3354729T (pt) 2024-04-11
AU2016325858A1 (en) 2018-04-19
CN108026521A (zh) 2018-05-11
CN110922481A (zh) 2020-03-27
IL288784A (en) 2022-02-01
IL302932B1 (en) 2026-01-01
IL302932A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
CN115869398B (zh) 抗garp抗体
JP6224759B2 (ja) 抗ｂ７−ｈ３抗体
US20230340118A1 (en) Anti-cd147 antibody
HK40110144A (en) Anti-garp antibody
HK40023165A (en) Anti-garp antibody
HK1254310B (en) Anti-garp antibody

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant